EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA perspectives

How can we develop new treatments in ultra-rare sarcomas, as a model for ultra-rare tumours?
12th January 2024

Pierre Demolis
Chair of the Oncology Working Party and vice chair of the Scientific Advice Working Party (SAWP), European Medicines Agency
Agence nationale de sécurité du médicament et des produits de santé (ANSM)

The views expressed are personal views and not necessarily the views of ANSM or EMA

EU regulatory strategies and review of Regulations – a time of change

- **Reform of the EU pharmaceutical legislation**: review of the pharma legislation: " build a holistic, patient-centred, forward-looking EU Pharmaceutical Strategy"
- **European Health Data Space**
- **New Health Technology Assessment** (HTA) regulation
- **EMA regulatory science strategy** (further collaboration with HTAs/payers for their decision making on pricing and reimbursement
- **EC beating cancer plan** (e.g. focusing on prevention)

EMA – organisation and network

Management Board | **Executive Director** | **H-Div** | **V-Div**

CHMP | **PRAC** | **COMP** | **HMPC** | **PDCO** | **CAT** | **CVMP**

+ working parties

+ 8 scientific advisory groups

EU National Competent Authorities
~ 4000 European experts

EU institutions

European Commission

European Parliament

~ 50 National regulatory authorities worldwide (ICH)

Oncology Working Party and European Specialised Expert Community



Innovation and support – available tools